Exercising with Rheumatoid Arthritis
January 19, 2017
Psoriasis May Be Associated With Liver Disease, Research Shows
January 19, 2017
Show all

MS Drug Treatment Costs Start the Year Headed Up

The cost of drug treatments for multiple sclerosis continues to rise.

I don’t think this will surprise you. Multiple sclerosis drugs, some of the most expensive drugs there are, are getting even more expensive.

Drug industry analyst Eric Schmidt, quoted in the Boston Business Journal, reported that Biogen began the new year by upping the price of Tecfidera, Avonex and Plegridy 8%. Tysabri got a 3.5% price hike. This is on top of a 4% price boost in December 2015 and another 5% in May, 2016 for the first three drugs, and increases of 5% in July 2015 and January 2016 for Tysabri.

What does this mean in terms of dollars? Schmidt estimates a year of Tecfidera now costs about $83,000. Avonex and Plegridy are right up there, too, with a price tag of about $81,000.

The Biogen MS drugs aren’t the only ones with costs that continue to climb. Schmidt reports that Gilenya, made by Novartis, and Serono’s Rebif are in the high-priced group. And, on January 1, Teva boosted the price of Copaxone, the top-selling MS drug, by 8%, bringing it to around $76,000 a year.

Read full article: MS Drug Treatment Costs Start the Year Headed Up

Read Full Article: MS Drug Treatment Costs Start the Year Headed Up

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.